RedHill's stock is up 7.0% as it shares new data about experimental COVID-19 drug

Shares of Redhill Biopharma Ltd. gained 7.0% in premarket trading on Monday after the company said it had new data from a Phase 2/3 clinical study evaluating its experimental oral antiviral opaganib in severely ill, hospitalized COVID-19 patients. Redhill said the treatment candidate reduced mortality by 62% when evaluating 251 of the 475 patients enrolled in the study. Several companies developing COVID-19 drugs have shared new data since Friday, when Merck & Co. Inc. said its experimental oral COVID-19 treatment helped keep people out of the hospital and from dying. The news sent Merck's shares soaring and created widespread excitement among clinicians. RedHill's stock is down 45.9% for the year, while the broader S&P 500 [S: spx] is up 14.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

RedHill's stock is up 7.0% as it shares new data about experimental COVID-19 drug
Shares of Redhill Biopharma Ltd. gained 7.0% in premarket trading on Monday after the company said it had new data from a Phase 2/3 clinical study evaluating its experimental oral antiviral opaganib in severely ill, hospitalized COVID-19 patients. Redhill said the treatment candidate reduced mortality by 62% when evaluating 251 of the 475 patients enrolled in the study. Several companies developing COVID-19 drugs have shared new data since Friday, when Merck & Co. Inc. said its experimental oral COVID-19 treatment helped keep people out of the hospital and from dying. The news sent Merck's shares soaring and created widespread excitement among clinicians. RedHill's stock is down 45.9% for the year, while the broader S&P 500 [S: spx] is up 14.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.